化合物Beta-Lapachone T6407
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
25 mg | 4707-32-8 | ¥891.00 | 询底价 |
200 mg | 4707-32-8 | ¥3,380.00 | 询底价 |
100 mg | 4707-32-8 | ¥2,280.00 | 询底价 |
1 mL | 4707-32-8 | ¥318.00 | 询底价 |
1 mg | 4707-32-8 | ¥148.00 | 询底价 |
500 mg | 4707-32-8 | ¥5,190.00 | 询底价 |
50 mg | 4707-32-8 | ¥1,450.00 | 询底价 |
5 mg | 4707-32-8 | ¥297.00 | 询底价 |
10 mg | 4707-32-8 | ¥493.00 | 询底价 |
Product Introduction
Bioactivity
英文名: β-Lapachone
描述: β-Lapachone (ARQ-501) 是一种萘醌类天然产物,是拓扑异构酶 I 抑制剂,通过抑制细胞周期进程来诱导细胞凋亡。
细胞实验: IC50 calculations for each cell line are determined by DNA amount (IS) and anchorage-dependent colony formation (CF) assays. For the CF assay, cells are seeded at 500 viable cells/well in 6-well plates and incubated overnight, then treated with equal volumes of media containing beta-lapachone at final concentrations ranging from 0.005 to 50 μM in half-log increments (controls were treated with 0.25% DMSO, equivalent to the highest dose of beta-lapachonc used) for 4 hour or for continuous 12-hour exposures. Plates (3 wells/condition) are stained with crystal violet, and colonies of >50 normal-appearing cells are enumerated. IC50 values for various cells are calculated using drug doses with numbers of colonies surrounding 50% of control. For DNA assays, plates are harvested for IC50 determinations 8 days after treatment using a CytoFluor 2350 fluorescence measurement system. Six-well samplings are included in the calculation of DNA fluor units for each dose. A graph of beta-lapachone dose versus percentage control DNA in fluor units is used to calculate each IC50. All experiments are repeated at least twice, each in duplicate. (Only for Reference)
激酶实验: Topoisomerase I Catalytic Actioity Assay [1]: Topoisomerase I Catalytic Actioity Assay: The enzymatic activity is analyzed by the DNA unwinding assay. DNA topoisomerase I, from TopoGEN (1 unit, which is defined as the amount of enzyme that converts 0.5 μg of superhelical DNA to the relaxed state in 30 minutes at 37 °C), is incubated with 0.5 μg of 6x174 RF DNA, in the presence or absence of Beta-Lapachone, in 20 μL of relaxation buffer (50 mM Tris (pH 7.5). 50 mM KCI, 10 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM EDTA, 30 μg/mL bovine serum albumin) for 30 minutes at 37 °C. Reactions are stopped by adding 1% SDS and proteinase K (50 μg/mL). After an additional 1-hour incubation at 37 °C, the products are separated by electrophoresis in 1% agarose gel in TAE buffer (0.04 M tris acetate, 0.001 M EDTA). The gel is stained with ethidium bromide after electrophoresis. The photographic negative is scanned with an NIH image analysis system.
体外活性: Beta-Lapachone inhibits DNA relaxation induced by DNA topoisomerase I in a dose-dependent manner. [1] Treatment of beta-lapachone (100 nM or greater) results in >95% inhibition of Topo I DNA unwinding activity compared to the DMSO control. beta-lapachone (1-5 μM) causes a block in G0/G1 of the cell cycle and induces apoptosis by locking Topo I onto DNA and blocking replication fork movement in HL-60 and three human prostate cancer (DU-145, PC-3, and LNCaP) cells. [2] Beta-Lapachone facilitates the migration of mouse 3T3 fibroblasts and human endothelial EAhy926 cells through different MAPK signaling pathways, and thus accelerates scrape-wound healing in vitro. [3] In addition, beta-Lapachone inhibits purified recombinant IDO1 activity through uncompetitive inhibition with IC50 of 0.44 μM, and beta-lapachone also exhibits superior retention of intracellular IDO1 inhibitory activity with an IC50 of 1.0 μM, partially dependent on biotransformation by NQO1. [4] Beta-lapachone induces programmed necrosis of NQO1+ cancer cells by NQO1-dependent reactive oxygen species (ROS) formation and PARP1 hyperactivation. [5]
体内活性: Beta-lapachone treatment (50 mg/kg) leads to potent inhibition of in vivo tumor growth in a xenograft mouse model of human ovarian cancer, and the combination of beta-lapachone and taxol produces a synergistic induction of apoptosis. [6] In normal and diabetic (db/db) mice, treatment of beta-lapachone results in a faster healing process than vehicle only. [3]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: Ethanol : 12.1 mg/mL (50 mM)
DMSO : 50 mg/mL (206.38 mM)
关键字: NSC26326 | Topoisomerase | b-Lapachone | Inhibitor | β-Lapachone | NSC 26326 | Apoptosis | ARQ501 | ARQ 501 | Autophagy | β Lapachone | inhibit | βLapachone | SL 11001 | SL11001
相关产品: IDO1-IN-5 | IDO1-IN-2 | PF-06840003 | Linrodostat | IDO-IN-5 | IDO-IN-12 | IDO-IN-8 | IDO5L | IDO1-IN-1 | IDO-IN-9
相关库: Drug Repurposing Compound Library | ReFRAME Related Library | Immuno-Oncology Compound Library | Anti-Metabolism Disease Compound Library | Inhibitor Library | Traditional Chinese Medicine Monomer Library | Natural Product Library for HTS | DNA Damage & Repair Compound Library | Autophagy Compound Library | Bioactive Compound Library
化合物Beta-Lapachone T6407信息由TargetMol中国为您提供,如您想了解更多关于化合物Beta-Lapachone T6407报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途